Abstract
Atherosclerosis is a progressive inflammatory disorder of the arterial vessel wall characterized by substantial infiltration of macrophages, which exert both favourable and detrimental functions. Early in atherogenesis, macrophages can clear cytotoxic lipoproteins and dead cells, preventing cytotoxicity. Efferocytosis — the efficient clearance of dead cells by macrophages — is crucial for preventing secondary necrosis and stimulating the release of anti-inflammatory cytokines. In addition, macrophages can promote tissue repair and proliferation of vascular smooth muscle cells, thereby increasing plaque stability. However, advanced atherosclerotic plaques contain large numbers of pro-inflammatory macrophages that secrete matrix-degrading enzymes, induce death in surrounding cells and contribute to plaque destabilization and rupture. Importantly, macrophages in the plaque can undergo apoptosis and several forms of regulated necrosis, including necroptosis, pyroptosis and ferroptosis. Regulated necrosis has an important role in the formation and expansion of the necrotic core during plaque progression, and several triggers for necrosis are present within atherosclerotic plaques. This Review focuses on the various forms of programmed macrophage death in atherosclerosis and the pharmacological interventions that target them as a potential means of stabilizing vulnerable plaques and improving the efficacy of currently available anti-atherosclerotic therapies.
Key points
-
Programmed death of macrophages, including apoptosis, necroptosis, pyroptosis and ferroptosis, has a role in atherogenesis and vulnerable plaque formation.
-
A balanced interplay exists between these forms of cell death; inhibiting one form can result in the activation of another.
-
Both invasive and non-invasive techniques can identify plaques that might benefit from therapy targeting programmed macrophage death, whereas specific cell death-related biomarkers can aid patient selection for treatment.
-
In early atherosclerotic plaques, the selective removal of macrophages via macrophage-specific death could have plaque-stabilizing effects.
-
In advanced atherosclerotic plaques, sufficient capacity for efferocytosis is essential to prevent secondary necrosis.
-
In addition to the use of inhibitors of necroptosis, pyroptosis or ferroptosis, employing resolvins or autophagy inducers represents a promising strategy to target programmed macrophage death as they can increase efferocytosis.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lusis, A. J. Atherosclerosis. Nature 407, 233–241 (2000).
Kockx, M. M. & Herman, A. G. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc. Res. 45, 736–746 (2000).
Virmani, R. et al. in The Vulnerable Atherosclerotic Plaque: Strategies for Diagnosis and Management (eds. Virmani, R., Narula, J., Leon, M. & Willerson, J.) 21–36 (Blackwell Futura, 2007).
Wilson, H. M. Macrophages heterogeneity in atherosclerosis — implications for therapy. J. Cell Mol. Med. 14, 2055–2065 (2010).
Schrijvers, D. M., De Meyer, G. R., Herman, A. G. & Martinet, W. Phagocytosis in atherosclerosis: molecular mechanisms and implications for plaque progression and stability. Cardiovasc. Res. 73, 470–480 (2007).
Martinet, W. & Kockx, M. M. Apoptosis in atherosclerosis: focus on oxidized lipids and inflammation. Curr. Opin. Lipidol. 12, 535–541 (2001).
Puylaert, P., Zurek, M., Rayner, K. J., De Meyer, G. R. Y. & Martinet, W. Regulated necrosis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 42, 1283–1306 (2022).
Bedoui, S., Herold, M. J. & Strasser, A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat. Rev. Mol. Cell Biol. 21, 678–695 (2020).
Gui, Y., Zheng, H. & Cao, R. Y. Foam cells in atherosclerosis: novel insights into its origins, consequences, and molecular mechanisms. Front. Cardiovasc. Med. 9, 845942 (2022).
Boada-Romero, E., Martinez, J., Heckmann, B. L. & Green, D. R. The clearance of dead cells by efferocytosis. Nat. Rev. Mol. Cell Biol. 21, 398–414 (2020).
Xiao, Z. et al. Programmed cell death and lipid metabolism of macrophages in NAFLD. Front. Immunol. 14, 1118449 (2023).
Seimon, T. & Tabas, I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J. Lipid Res. 50, S382–S387 (2009).
van Vlijmen, B. J. et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ. Res. 88, 780–786 (2001).
Liu, J. et al. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 25, 174–179 (2005).
Arai, S. et al. A role for the apoptosis inhibitory factor AIM/Spα/Api6 in atherosclerosis development. Cell Metab. 1, 201–213 (2005).
Babaev, V. R. et al. Macrophage IKKα deficiency suppresses akt phosphorylation, reduces cell survival, and decreases early atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 36, 598–607 (2016).
Rayner, K. J. Cell death in the vessel wall: the good, the bad, the ugly. Arterioscler. Thromb. Vasc. Biol. 37, e75–e81 (2017).
Schrijvers, D. M., De Meyer, G. R., Kockx, M. M., Herman, A. G. & Martinet, W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arteroscler. Thromb. Vasc. Biol. 25, 1256–1261 (2005).
Coornaert, I. et al. Impact of myeloid RIPK1 gene deletion on atherogenesis in ApoE-deficient mice. Atherosclerosis 322, 51–60 (2021).
Yurdagul, A. Jr, Doran, A. C., Cai, B., Fredman, G. & Tabas, I. A. Mechanisms and consequences of defective efferocytosis in atherosclerosis. Front. Cardiovasc. Med. 4, 86 (2018).
Rogers, C. et al. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat. Commun. 10, 1689 (2019).
Martinet, W., Schrijvers, D. M. & De Meyer, G. R. Necrotic cell death in atherosclerosis. Basic Res. Cardiol. 106, 749–760 (2011).
Mallat, Z. et al. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 99, 348–353 (1999).
Li, Y. et al. Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. J. Biol. Chem. 281, 6707–6717 (2006).
Thorp, E., Cui, D., Schrijvers, D. M., Kuriakose, G. & Tabas, I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/- mice. Arterioscler. Thromb. Vasc. Biol. 28, 1421–1428 (2008).
Ait-Oufella, H. et al. Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28, 1429–1431 (2008).
Wang, W. et al. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 (V617F) mice. Circ. Res. 123, e35–e47 (2018).
Kojima, Y. et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536, 86–90 (2016).
Brouckaert, G. et al. Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol. Biol. Cell 15, 1089–1100 (2004).
Shlomovitz, I., Speir, M. & Gerlic, M. Flipping the dogma - phosphatidylserine in non-apoptotic cell death. Cell Commun. Signal. 17, 139 (2019).
Kumar, D., Pandit, R. & Yurdagul, A. Jr. Mechanisms of continual efferocytosis by macrophages and its role in mitigating atherosclerosis. Immunometabolism 5, e00017 (2023).
Yurdagul, A. Jr et al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab. 31, 518–533.e10 (2020).
Doran, A. C. Inflammation resolution: implications for atherosclerosis. Circ. Res. 130, 130–148 (2022).
Majno, G. & Joris, I. Apoptosis, oncosis, and necrosis. An overview of Cell death. Am. J. Pathol. 146, 3–15 (1995).
Crisby, M. et al. Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Atherosclerosis 130, 17–27 (1997).
Tabas, I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Aterioscler. Thromb. Vasc. Biol. 25, 2255–2264 (2005).
Kalinina, N. et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler. Thromb. Vasc. Biol. 24, 2320–2325 (2004).
de Souza, A. W., Westra, J., Limburg, P. C., Bijl, M. & Kallenberg, C. G. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun. Rev. 11, 909–917 (2012).
Kanellakis, P. et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arterioscler. Thromb. Vasc. Biol. 31, 313–319 (2011).
Cuccurullo, C. et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 26, 2716–2723 (2006).
Calkin, A. C. et al. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia 51, 1731–1740 (2008).
Yin, Y. X. et al. The effect of simvastatin on the expression of high mobility group box-1 protein in atherosclerotic rats [Chinese]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 22, 306–308 (2010).
Liu, M. et al. Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE−/− mice by downregulating the HMGB1-RAGE axis. Acta Pharmacol. Sin. 34, 830–836 (2013).
Zhou, Y. et al. Verification of ferroptosis and pyroptosis and identification of PTGS2 as the hub gene in human coronary artery atherosclerosis. Free Radic. Biol. Med. 171, 55–68 (2021).
Uyy, E. et al. Regulated cell death joins in atherosclerotic plaque silent progression. Sci. Rep. 12, 2814 (2022).
Degterev, A. et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1, 112–119 (2005).
Degterev, A. et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4, 313–321 (2008).
Cho, Y. S. et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137, 1112–1123 (2009).
He, S. et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-α. Cell 137, 1100–1111 (2009).
Zhang, D. W. et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325, 332–336 (2009).
Dondelinger, Y. et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 7, 971–981 (2014).
Wang, H. et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol. Cell 54, 133–146 (2014).
Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H. & Vandenabeele, P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol. 15, 135–147 (2014).
Karunakaran, D. et al. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci. Adv. 2, e1600224 (2016).
Tian, F. et al. 5-Aminolevulinic acid-mediated sonodynamic therapy inhibits RIPK1/RIPK3-dependent necroptosis in THP-1-derived foam cells. Sci. Rep. 6, 21992 (2016).
Karshovska, E. et al. HIF-1α (hypoxia-inducible factor-1α) promotes macrophage necroptosis by regulating miR-210 and miR-383. Arterioscler. Thromb. Vasc. Biol. 40, 583–596 (2020).
Liu, C., Jiang, Z., Pan, Z. & Yang, L. The function, regulation and mechanism of programmed cell death of macrophages in atherosclerosis. Front. Cell Dev. Biol. 9, 809516 (2021).
Xu, Y. J., Zheng, L., Hu, Y. W. & Wang, Q. Pyroptosis and its relationship to atherosclerosis. Clin. Chim. Acta 476, 28–37 (2018).
Shi, J., Gao, W. & Shao, F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem. Sci. 42, 245–254 (2017).
Nirmala, J. G. & Lopus, M. Cell death mechanisms in eukaryotes. Cell Biol. Toxicol. 36, 145–164 (2020).
Shi, X., Xie, W. L., Kong, W. W., Chen, D. & Qu, P. Expression of the NLRP3 inflammasome in carotid atherosclerosis. J. Stroke Cerebrovasc. Dis. 24, 2455–2466 (2015).
Rajamaki, K. et al. p38δ MAPK: a novel regulator of NLRP3 inflammasome activation with increased expression in coronary atherogenesis. Arterioscler. Thromb. Vasc. Biol. 36, 1937–1946 (2016).
Paramel Varghese, G. et al. NLRP3 inflammasome expression and activation in human atherosclerosis. J. Am. Heart Assoc. 5, e003031 (2016).
Rajamäki, K. et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5, e11765 (2010).
Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 (2010).
Tall, A. R. & Westerterp, M. Inflammasomes, neutrophil extracellular traps, and cholesterol. J. Lipid Res. 60, 721–727 (2019).
Yalcinkaya, M. et al. Cholesterol accumulation in macrophages drives NETosis in atherosclerotic plaques via IL-1β secretion. Cardiovasc. Res. 119, 969–981 (2023).
Jiang, M. et al. Caspase-11-gasdermin D-mediated pyroptosis is involved in the pathogenesis of atherosclerosis. Front. Pharmacol. 12, 657486 (2021).
Son, S. J. et al. Triglyceride-induced macrophage cell death is triggered by caspase-1. Biol. Pharm. Bull. 36, 108–113 (2013).
Zheng, F., Xing, S., Gong, Z. & Xing, Q. NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis. Heart Lung Circ. 22, 746–750 (2013).
Zheng, F., Xing, S., Gong, Z., Mu, W. & Xing, Q. Silence of NLRP3 suppresses atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice. Mediators Inflamm. 2014, 507208 (2014).
Zeng, W. et al. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages. Sci. Rep. 11, 19305 (2021).
Sharma, A. et al. Specific NLRP3 inhibition protects against diabetes-associated atherosclerosis. Diabetes 70, 772–787 (2021).
van der Heijden, T. et al. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice-brief report. Arterioscler. Thromb. Vasc. Biol. 37, 1457–1461 (2017).
Gage, J., Hasu, M., Thabet, M. & Whitman, S. C. Caspase-1 deficiency decreases atherosclerosis in apolipoprotein E-null mice. Can. J. Cardiol. 28, 222–229 (2012).
Li, Y. et al. VX-765 attenuates atherosclerosis in ApoE deficient mice by modulating VSMCs pyroptosis. Exp. Cell Res. 389, 111847 (2020).
Whitman, S. C., Ravisankar, P. & Daugherty, A. Interleukin-18 enhances atherosclerosis in apolipoprotein E−/− mice through release of interferon-γ. Circ. Res. 90, E34–E38 (2002).
Elhage, R. et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 59, 234–240 (2003).
Kirii, H. et al. Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23, 656–660 (2003).
Borborema, M. E. A., Crovella, S., Oliveira, D. & de Azevêdo Silva, J. Inflammasome activation by NLRP1 and NLRC4 in patients with coronary stenosis. Immunobiology 225, 151940 (2020).
Hakimi, M., Peters, A., Becker, A., Böckler, D. & Dihlmann, S. Inflammation-related induction of absent in melanoma 2 (AIM2) in vascular cells and atherosclerotic lesions suggests a role in vascular pathogenesis. J. Vasc. Surg. 59, 794–803 (2014).
Paulin, N. et al. Double-strand DNA sensing aim2 inflammasome regulates atherosclerotic plaque vulnerability. Circulation 138, 321–323 (2018).
Pan, J. et al. AIM2 accelerates the atherosclerotic plaque progressions in ApoE−/− mice. Biochem. Biophys. Res. Commun. 498, 487–494 (2018).
Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012).
Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273–285 (2017).
Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).
Yan, H. F. et al. Ferroptosis: mechanisms and links with diseases. Signal. Transduct. Target. Ther. 6, 49 (2021).
Rasool, A., Mahmoud, T. & O’Tierney-Ginn, P. Lipid aldehydes 4-hydroxynonenal and 4-hydroxyhexenal exposure differentially impact lipogenic pathways in human placenta. Biology 12, 527 (2023).
Fruhwirth, G. O., Loidl, A. & Hermetter, A. Oxidized phospholipids: from molecular properties to disease. Biochim. Biophys. Acta 1772, 718–736 (2007).
Hassannia, B., Vandenabeele, P. & Vanden Berghe, T. Targeting ferroptosis to iron out cancer. Cancer Cell 35, 830–849 (2019).
Youssef, L. A. et al. Increased erythrophagocytosis induces ferroptosis in red pulp macrophages in a mouse model of transfusion. Blood 131, 2581–2593 (2018).
De Meyer, G. R. et al. Platelet phagocytosis and processing of β-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ. Res. 90, 1197–1204 (2002).
Kockx, M. M. et al. Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 440–446 (2003).
Yuan, X. M., Li, W., Baird, S. K., Carlsson, M. & Melefors, O. Secretion of ferritin by iron-laden macrophages and influence of lipoproteins. Free Radic. Res. 38, 1133–1142 (2004).
Yuan, X. M., Anders, W. L., Olsson, A. G. & Brunk, U. T. Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis. Atherosclerosis 124, 61–73 (1996).
Fuhrman, B., Oiknine, J. & Aviram, M. Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL, and affects their secretory properties. Atherosclerosis 111, 65–78 (1994).
Yuan, X. M., Brunk, U. T. & Olsson, A. G. Effects of iron- and hemoglobin-loaded human monocyte-derived macrophages on oxidation and uptake of LDL. Arterioscler. Thromb. Vasc. Biol. 15, 1345–1351 (1995).
Meng, Z. et al. HMOX1 upregulation promotes ferroptosis in diabetic atherosclerosis. Life Sci. 284, 119935 (2021).
David, K. K., Andrabi, S. A., Dawson, T. M. & Dawson, V. L. Parthanatos, a messenger of death. Front. Biosci. 14, 1116–1128 (2009).
Martinet, W., Knaapen, M. W., De Meyer, G. R., Herman, A. G. & Kockx, M. M. Oxidative DNA damage and repair in experimental atherosclerosis are reversed by dietary lipid lowering. Circ. Res. 88, 733–739 (2001).
Martinet, W., Knaapen, M. W., De Meyer, G. R., Herman, A. G. & Kockx, M. M. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 106, 927–932 (2002).
Oumouna-Benachour, K. et al. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death. Circulation 115, 2442–2450 (2007).
Xie, J. J. et al. Poly (ADP-ribose) polymerase inhibition attenuates atherosclerotic plaque development in ApoE-/- mice with hyperhomocysteinemia. J. Atheroscler. Thromb. 16, 641–653 (2009).
Liu, Y. & Levine, B. Autosis and autophagic cell death: the dark side of autophagy. Cell Death Differ. 22, 367–376 (2015).
Nah, J., Zablocki, D. & Sadoshima, J. Autosis: a new target to prevent cell death. JACC Basic Transl. Sci. 5, 857–869 (2020).
Hassanpour, M. et al. Role of autophagy in atherosclerosis: foe or friend? J. Inflamm. 16, 8 (2019).
De Meyer, G. R. Y. et al. Autophagy in vascular disease. Circ. Res. 116, 468–479 (2015).
Koenig, W. & Khuseyinova, N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler. Thromb. Vasc. Biol. 27, 15–26 (2007).
Bassuk, S. S., Rifai, N. & Ridker, P. M. High-sensitivity C-reactive protein: clinical importance. Curr. Probl. Cardiol. 29, 439–493 (2004).
Thompson, A. et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375, 1536–1544 (2010).
Wimmer, K., Sachet, M. & Oehler, R. Circulating biomarkers of cell death. Clin. Chim. Acta 500, 87–97 (2020).
Vucur, M. et al. Elevated serum levels of mixed lineage kinase domain-like protein predict survival of patients during intensive care unit treatment. Dis. Markers 2018, 1983421 (2018).
Hu, B. et al. Prognostic and clinicopathological significance of MLKL expression in cancer patients: a meta-analysis. BMC Cancer 18, 736 (2018).
Shen, H. et al. Pyroptosis executive protein GSDMD as a biomarker for diagnosis and identification of Alzheimer’s disease. Brain Behav. 11, e02063 (2021).
Wang, D. et al. Assessment of pyroptosis-related indicators as potential biomarkers and their association with severity in patients with liver cirrhosis. J. Inflamm. Res. 14, 3185–3196 (2021).
Tang, D., Chen, X., Kang, R. & Kroemer, G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 31, 107–125 (2021).
Wiernicki, B. et al. Excessive phospholipid peroxidation distinguishes ferroptosis from other cell death modes including pyroptosis. Cell Death Dis. 11, 922 (2020).
Szilágyi, M. et al. Circulating cell-free nucleic acids: main characteristics and clinical application. Int. J. Mol. Sci. 21, 6827 (2020).
Polina, I. A., Ilatovskaya, D. V. & DeLeon-Pennell, K. Y. Cell free DNA as a diagnostic and prognostic marker for cardiovascular diseases. Clin. Chim. Acta 503, 145–150 (2020).
Zemmour, H. et al. Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA. Nat. Commun. 9, 1443 (2018).
Mushenkova, N. V. et al. Current advances in the diagnostic imaging of atherosclerosis: insights into the pathophysiology of vulnerable plaque. Int. J. Mol. Sci. 21, 2992 (2020).
De Dominicis, C. et al. [18F]ZCDD083: a PFKFB3-targeted PET tracer for atherosclerotic plaque imaging. ACS Med. Chem. Lett. 11, 933–939 (2020).
Liu, H., Xiang, C., Wang, Z. & Song, Y. Identification of potential ferroptosis-related biomarkers and immune infiltration in human coronary artery atherosclerosis. Int. J. Gen. Med. 15, 2979–2990 (2022).
Martinet, W., Coornaert, I., Puylaert, P. & De Meyer, G. R. Y. Macrophage death as a pharmacological target in atherosclerosis. Front. Pharmacol. 10, 306 (2019).
Croons, V., Martinet, W., Herman, A. G., Timmermans, J. P. & De Meyer, G. R. Selective clearance of macrophages in atherosclerotic plaques by the protein synthesis inhibitor cycloheximide. J. Pharmacol. Exp. Ther. 320, 986–993 (2007).
Kojima, Y., Weissman, I. L. & Leeper, N. J. The role of efferocytosis in atherosclerosis. Circulation 135, 476–489 (2017).
Garabuczi, E., Sarang, Z. & Szondy, Z. Glucocorticoids enhance prolonged clearance of apoptotic cells by upregulating liver X receptor, peroxisome proliferator-activated receptor-δ and UCP2. Biochim. Biophys. Acta 1853, 573–582 (2015).
Maderna, P., Yona, S., Perretti, M. & Godson, C. Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac(2-26). J. Immunol. 174, 3727–3733 (2005).
Scannell, M. et al. Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J. Immunol. 178, 4595–4605 (2007).
Fredman, G. et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat. Commun. 7, 12859 (2016).
Hasturk, H. et al. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler. Thromb. Vasc. Biol. 35, 1123–1133 (2015).
Viola, J. R. et al. Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ. Res. 119, 1030–1038 (2016).
Lee, H. N., Kundu, J. K., Cha, Y. N. & Surh, Y. J. Resolvin D1 stimulates efferocytosis through p50/p50-mediated suppression of tumor necrosis factor-α expression. J. Cell Sci. 126, 4037–4047 (2013).
Fredman, G. & Serhan, C. N. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem. J. 437, 185–197 (2011).
van Gils, J. M. et al. The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat. Immunol. 13, 136–143 (2012).
Schlegel, M. et al. Silencing myeloid netrin-1 induces inflammation resolution and plaque regression. Circ. Res. 129, 530–546 (2021).
Wanschel, A. et al. Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler. Thromb. Vasc. Biol. 33, 886–893 (2013).
Proto, J. D. et al. Regulatory T cells promote macrophage efferocytosis during inflammation resolution. Immunity 49, 666–677.e6 (2018).
Karunakaran, D. et al. RIPK1 expression associates with inflammation in early atherosclerosis in humans and can be therapeutically silenced to reduce NF-κB activation and atherogenesis in mice. Circulation 143, 163–177 (2021).
Puylaert, P. et al. The impact of RIPK1 kinase inhibition on atherogenesis: a genetic and a pharmacological approach. Biomedicines 10, 1016 (2022).
Rasheed, A. et al. Loss of MLKL (mixed lineage kinase domain-like protein) decreases necrotic core but increases macrophage lipid accumulation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 40, 1155–1167 (2020).
Hosseini, Z. et al. Resolvin D1 enhances necroptotic cell clearance through promoting macrophage fatty acid oxidation and oxidative phosphorylation. Arterioscler. Thromb. Vasc. Biol. 41, 1062–1075 (2021).
Lin, J. et al. A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep. 3, 200–210 (2013).
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
Bhaskar, V. et al. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis 216, 313–320 (2011).
Gomez, D. et al. Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice. Nat. Med. 24, 1418–1429 (2018).
Ridker, P. M., MacFadyen, J. G., Thuren, T. & Libby, P. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur. Heart J. 41, 2153–2163 (2019).
Koritala, T. et al. Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: a narrative review. Infez. Med. 29, 495–503 (2021).
Thompson, P. L. & Nidorf, S. M. Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial. J. Thorac. Dis. 10, 695–698 (2018).
Olsen, M. B. et al. Targeting the inflammasome in cardiovascular disease. JACC Basic Transl. Sci. 7, 84–98 (2022).
Martinez, G. J. et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J. Am. Heart Assoc. 4, e002128 (2015).
Nidorf, M. & Thompson, P. L. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am. J. Cardiol. 99, 805–807 (2007).
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A. & Thompson, P. L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 61, 404–410 (2013).
Soehnlein, O. & Tall, A. R. AIMing 2 treat atherosclerosis. Nat. Rev. Cardiol. 19, 567–568 (2022).
Evavold, C. L. et al. The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages. Immunity 48, 35–44.e36 (2018).
Hu, J. J. et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat. Immunol. 21, 736–745 (2020).
Humphries, F. et al. Succination inactivates gasdermin D and blocks pyroptosis. Science 369, 1633–1637 (2020).
Luo, M., Sun, Q., Zhao, H., Tao, J. & Yan, D. The effects of dimethyl fumarate on atherosclerosis in the apolipoprotein E-Deficient mouse model with streptozotocin-induced hyperglycemia mediated by the nuclear factor erythroid 2-related factor 2/antioxidant response element (Nrf2/ARE) signaling pathway. Med. Sci. Monit. 25, 7966–7975 (2019).
Matheeussen, V. et al. Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. Basic Res. Cardiol. 108, 3504 (2013).
Wisniewska, A. et al. The antiatherosclerotic action of 1G244 - An inhibitor of dipeptidyl peptidases 8/9 - is mediated by the induction of macrophage death. Eur. J. Pharmacol. 944, 175566 (2023).
Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180–1191 (2014).
Zilka, O. et al. On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Cent. Sci. 3, 232–243 (2017).
Skouta, R. et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136, 4551–4556 (2014).
Bai, T., Li, M., Liu, Y., Qiao, Z. & Wang, Z. Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid peroxidation and endothelial dysfunction in mouse aortic endothelial cell. Free Radic. Biol. Med. 160, 92–102 (2020).
Guo, Z. et al. Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice. Free Radic. Biol. Med. 44, 343–352 (2008).
Hofmans, S. et al. Novel ferroptosis inhibitors with improved potency and ADME properties. J. Med. Chem. 59, 2041–2053 (2016).
Devisscher, L. et al. Discovery of novel, drug-like ferroptosis inhibitors with in vivo efficacy. J. Med. Chem. 61, 10126–10140 (2018).
Puylaert, P. et al. Effect of erythrophagocytosis-induced ferroptosis during angiogenesis in atherosclerotic plaques. Angiogenesis 26, 505–522 (2023).
Xu, J., Han, X., Xia, N., Zhao, Q. & Cheng, Z. IL-37 suppresses macrophage ferroptosis to attenuate diabetic atherosclerosis via the NRF2 pathway. Exp. Ther. Med. 25, 289 (2023).
Nikoletopoulou, V., Markaki, M., Palikaras, K. & Tavernarakis, N. Crosstalk between apoptosis, necrosis and autophagy. Biochim. Biophys. Acta 1833, 3448–3459 (2013).
Lin, Y., Devin, A., Rodriguez, Y. & Liu, Z. G. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 13, 2514–2526 (1999).
Ofengeim, D. & Yuan, J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat. Rev. Mol. Cell Biol. 14, 727–736 (2013).
Fritsch, M. et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature 575, 683–687 (2019).
Schneider, K. S. et al. The inflammasome drives GSDMD-independent secondary pyroptosis and IL-1 release in the absence of caspase-1 protease activity. Cell Rep. 21, 3846–3859 (2017).
Speir, M. & Lawlor, K. E. RIP-roaring inflammation: RIPK1 and RIPK3 driven NLRP3 inflammasome activation and autoinflammatory disease. Semin. Cell Dev. Biol. 109, 114–124 (2021).
Lawlor, K. E. et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nat. Commun. 6, 6282 (2015).
Tao, L. et al. The kinase receptor-interacting protein 1 is required for inflammasome activation induced by endoplasmic reticulum stress. Cell Death Dis. 9, 641 (2018).
Puylaert, P. et al. Gasdermin D deficiency limits the transition of atherosclerotic plaques to an inflammatory phenotype in ApoE knock-out mice. Biomedicines 10, 1171 (2022).
Zheng, M. & Kanneganti, T. D. The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis). Immunol. Rev. 297, 26–38 (2020).
Liu, W. et al. Erythroid lineage Jak2V617F expression promotes atherosclerosis through erythrophagocytosis and macrophage ferroptosis. J. Clin. Invest. 132, e155724 (2022).
Michel, J. B., Virmani, R., Arbustini, E. & Pasterkamp, G. Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur. Heart J. 32, 1977–1985 (2011).
Dutra, F. F. et al. Hemolysis-induced lethality involves inflammasome activation by heme. Proc. Natl Acad. Sci. USA 111, E4110–E4118 (2014).
Cherubini, A. et al. Role of antioxidants in atherosclerosis: epidemiological and clinical update. Curr. Pharm. Des. 11, 2017–2032 (2005).
Kim, H. J. et al. NecroX as a novel class of mitochondrial reactive oxygen species and ONOO- scavenger. Arch. Pharm. Res. 33, 1813–1823 (2010).
Grootaert, M. O. et al. NecroX-7 reduces necrotic core formation in atherosclerotic plaques of Apoe knockout mice. Atherosclerosis 252, 166–174 (2016).
Kim, E. et al. Pharmacokinetics and tolerability of LC28-0126, a novel necrosis inhibitor, after multiple ascending doses: a phase I randomized, double-blind, placebo-controlled study in healthy male subjects. Clin. Ther. 42, 1946–1954.e2 (2020).
Marlevi, D. & Edelman, E. R. Vascular lesion-specific drug delivery systems: JACC state-of-the-art review. J. Am. Coll. Cardiol. 77, 2413–2431 (2021).
Bejarano, J. et al. Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Theranostics 8, 4710–4732 (2018).
Tao, H. et al. Scavenging of reactive dicarbonyls with 2-hydroxybenzylamine reduces atherosclerosis in hypercholesterolemic Ldlr-/- mice. Nat. Commun. 11, 4084 (2020).
Pitchford, L. M. et al. Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial. BMC Pharmacol. Toxicol. 21, 3 (2020).
Huang, J. et al. Scavenging dicarbonyls with 5’-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance. Mol. Metab. 67, 101651 (2023).
Martinet, W., Verheye, S. & De Meyer, G. R. Y. Selective depletion of macrophages in atherosclerotic plaques via macrophage-specific initiation of cell death. Trends Cardiovasc. Med. 17, 69–75 (2007).
Verheye, S. et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J. Am. Coll. Cardiol. 49, 706–715 (2007).
Wang, X. et al. Knockdown of mTOR by lentivirus-mediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein E-deficient mice. Int. J. Mol. Med. 32, 1215–1221 (2013).
Zhai, C. et al. Selective inhibition of PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage and vulnerability of atherosclerotic plaque. PLoS ONE 9, e90563 (2014).
Martinet, W. et al. Drug-induced macrophage autophagy in atherosclerosis: for better or worse? Basic Res. Cardiol. 108, 321 (2013).
Martinet, W. et al. Everolimus triggers cytokine release by macrophages: rationale for stents eluting everolimus and a glucocorticoid. Arterioscler. Thromb. Vasc. Biol. 32, 1228–1235 (2012).
Acknowledgements
The authors were supported by iBOF (interuniversitair Bijzonder Onderzoeksfonds) ATLANTIS (grant iBOF-21-053) and the FWO-Flanders (grant G026723N).
Author information
Authors and Affiliations
Contributions
All the authors researched data for the article and discussed the content of the article. G.R.Y.D.M. and W.M. wrote the manuscript. All the authors reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Cardiology thanks Joseph Boyle; Edward Thorp, who co-reviewed with Kristofor Glinton; and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
De Meyer, G.R.Y., Zurek, M., Puylaert, P. et al. Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets. Nat Rev Cardiol 21, 312–325 (2024). https://doi.org/10.1038/s41569-023-00957-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-023-00957-0
